BibTex RIS Kaynak Göster

Type Iv Renal Tubular Acidosis Due To Trimethoprim Type Iv Rta Due To Trimethoprim

Yıl 2011, Sayı: 3, 171 - 173, 01.09.2011

Öz

Various malignancies, primary immune deficiency, HIV/AIDS, organ / bone marrow transplantation, corticosteroids, immunosuppressive agents and the use of some drugs lead to the weakening of the immune system and prepare the ground for pneumocyctis jeruvici pneumonia. Trimethoprim-sulfamethoxazole TMP-SMX is used in pneumocyctis jeruvici pneumonia. Type IV renal tubular acidosis RTA due to TMP that used in treatment is rare. We present 71 years old female patient who had Type IV RTA due to TMP

Kaynakça

  • Thomas CF, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004;350:2487-98
  • William AP. Sulfonamides, Trimethoprim-sulfamethoxazole, quınolones. Brunton LL, Lazo ZS, Parker KL. Goodman & Gilman’s the pharmacologıcal basis of therapeutics. The McGraw- Hill Companies. 11th ed. 2006; 458-63.
  • Lin SH, Kuo AA, Yu FC, Lin YF. Reversible voltage- depent distal renal tubular acidosis in a patient receiving standart doses of trimethoprim- sulphamethoxazole. Nephrol Dial Transplant. 1997;12:1031-3.
  • Murphy JL, Griswold WR, Reznik VM, Mendoza SA. Trimethoprim / sulphamethoxazole- induced renal tubuler acidosis.Child Nephrol Urol.1990;10:49-50.
  • Domingo P, Ferrer S, Cruz J, Morla R, Ris J. Trimethoprim- sulphamethoxazole-induced renal tubuler acidosis in a patients with AIDS. Clin Infect Dis. 1995;20:1435-7.
  • Sheehan MT, Wen SF. Hyperkalemic renal tubuler acidosis induced by trimethoprim/sulphamethoxazole in an AIDS patient. Clin Nephrol.1998;50:188-93.
  • Margassery S, Bastani B. Life threatening hyperkalemia and acidosis secondary to trimethoprim- sulphamethoxazole treatment.J Nephrol. 2001;14:410-4.
  • Singer GG, Brenner BM. Fluid and electrolyte disturbances. Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al. Harrison’s Principles of Internal Medicine.The McGraw- Hill Companies.17th ed.2008;283-5.
  • Eiam-Ong S, Kurtzman NA, Sabatini S. Studies on the mechanism of trimethoprim-induced hyperkalemia. Kidney Int 1996;49:1372-8.
  • Mohan S,Jaitly M,Pogue VA,Cheng JT.Infl uence of concomitant prednisolone on trimethoprim-associated hyperkalaemia. J Antimicrob Chemother. 2009;64:850-2.
  • Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM. Trimethoprim-sulphamethoxazole-induced hyperkalamia in patients receiving inhibitors of the renin-angiotensin system: apopulation-based study.Arch Intern Med. 2010;170:1045-9.

Trimetoprime Bağlı Gelişen Tip IV Renal Tübüler Asidoz

Yıl 2011, Sayı: 3, 171 - 173, 01.09.2011

Öz

Çeşitli maligniteler, primer immün yetmezlik, HIV/AIDS, organ/kemik iliği nakli, kortikosteroid, immünsüpresif ajanlar ve bazı ilaçların kullanımı bağışıklık sisteminin zayıflamasına yol açarak pnömosistis jiroveci pnömonisine zemin hazırlar. Pnömosistis jiroveci pnömonisinde trimetoprim- sülfametoksazol TMP- SMX kullanılır. Tedavide kullanılan TMP’e bağlı gelişen Tip IV renal tübüler asidoz Tip IV RTA nadirdir. Burada TMP’e bağlı Tip IV renal tübüler asidoz gelişen 71 yaşında bayan hastayı sunuyoruz

Kaynakça

  • Thomas CF, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004;350:2487-98
  • William AP. Sulfonamides, Trimethoprim-sulfamethoxazole, quınolones. Brunton LL, Lazo ZS, Parker KL. Goodman & Gilman’s the pharmacologıcal basis of therapeutics. The McGraw- Hill Companies. 11th ed. 2006; 458-63.
  • Lin SH, Kuo AA, Yu FC, Lin YF. Reversible voltage- depent distal renal tubular acidosis in a patient receiving standart doses of trimethoprim- sulphamethoxazole. Nephrol Dial Transplant. 1997;12:1031-3.
  • Murphy JL, Griswold WR, Reznik VM, Mendoza SA. Trimethoprim / sulphamethoxazole- induced renal tubuler acidosis.Child Nephrol Urol.1990;10:49-50.
  • Domingo P, Ferrer S, Cruz J, Morla R, Ris J. Trimethoprim- sulphamethoxazole-induced renal tubuler acidosis in a patients with AIDS. Clin Infect Dis. 1995;20:1435-7.
  • Sheehan MT, Wen SF. Hyperkalemic renal tubuler acidosis induced by trimethoprim/sulphamethoxazole in an AIDS patient. Clin Nephrol.1998;50:188-93.
  • Margassery S, Bastani B. Life threatening hyperkalemia and acidosis secondary to trimethoprim- sulphamethoxazole treatment.J Nephrol. 2001;14:410-4.
  • Singer GG, Brenner BM. Fluid and electrolyte disturbances. Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al. Harrison’s Principles of Internal Medicine.The McGraw- Hill Companies.17th ed.2008;283-5.
  • Eiam-Ong S, Kurtzman NA, Sabatini S. Studies on the mechanism of trimethoprim-induced hyperkalemia. Kidney Int 1996;49:1372-8.
  • Mohan S,Jaitly M,Pogue VA,Cheng JT.Infl uence of concomitant prednisolone on trimethoprim-associated hyperkalaemia. J Antimicrob Chemother. 2009;64:850-2.
  • Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM. Trimethoprim-sulphamethoxazole-induced hyperkalamia in patients receiving inhibitors of the renin-angiotensin system: apopulation-based study.Arch Intern Med. 2010;170:1045-9.
Toplam 11 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Case Report
Yazarlar

İrfan Yavaşoğlu

Gökhan Sargın

Gürhan Kadıköylü

Ali Zahit Bolaman

Yayımlanma Tarihi 1 Eylül 2011
Yayımlandığı Sayı Yıl 2011Sayı: 3

Kaynak Göster

EndNote Yavaşoğlu İ, Sargın G, Kadıköylü G, Bolaman AZ (01 Eylül 2011) Trimetoprime Bağlı Gelişen Tip IV Renal Tübüler Asidoz. Acıbadem Üniversitesi Sağlık Bilimleri Dergisi 3 171–173.